Indications and uses
• controls the symptoms of diarrhea, including Traveler's Diarrhea
• controls the symptoms of diarrhea, including Traveler's Diarrhea
• drink plenty of clear fluid to help prevent dehydration caused by diarrhea • find right dose on chart. If possible, use weight to dose; otherwise use age. • Use only enclosed dosing cup specifically designed for use with this product. Do not use any other dosing device. • TSP = teaspoonful = milliliter adults and children 12 years and older 4 teaspoonfuls (20 mL) after the first loose stool movement; 2 teaspoonf...
(in each 5 mL teaspoonful)
Loperamide HCl 1 mg
Anti-diarrheal
Alergy alert: Do not use if you have ever had a rash or other allergic reaction to loperamide HCl
Heart alert: Taking more than directed can cause serious heart problems or death
Do not use if you have bloody or black stool
Ask a doctor before use if you have
Ask doctor or pharmacist before use if you are taking antibiotics
When using this product tiredness, drowsiness or dizziness may occur.Be careful when driving or operating machinery.
Stop use and ask a doctor if
If pregnant or breast-feeding, ask a health professional before use
In case of overdose, get medical help or contact a Poison Control Center right away.
adults and children 12 years and older | 4 teaspoonfuls (20 mL) after the first loose stool movement; 2 teaspoonfuls (10 mL) after each subsequent loose stool; but no more than 8 teaspoonfuls (40 mL) a day |
children 9-11 years (60-95 lbs) | 2 teaspoonfuls (10 mL) after the first loose stool movement; 1 teaspoonfuls (5 mL) after each subsequent loose stool; but no more than 6 teaspoonfuls (30 mL) a day |
children 6-8 years (48-59 lbs) | 2teaspoonfuls (10 mL) after the first loose stool movement; 1 teaspoonfuls (5 mL) after each subsequent loose stool; but no more than 4 teaspoonfuls (20 mL) a day |
children 2-5 years (34 to 47 lbs) | ask a doctor |
children under 2 years (up to 33 lbs) | do not use |
alcohol (0.5%), benzoic acid, cherry flavor, glycerin, mint flavor, propylene glycol, purified water, sodium benzoate, sorbitol solution, sucrose. Citric acid may be used to adjust pH
Call 1-800-262-9010
Mon. - Thurs. 9:00 am - 4:30 pm EST,
Fri. 9:00 am - 2:30 pm EST
Serious side effects associated with use of this product may be reported to this number.
Manufactured by:
Hi-Tech Pharmacal Co., Inc.
Amityville, NY 11701
Rev. 618:07 05/18
Relabeled By: Preferred Pharmaceuticals Inc.

Rx Choice
NDC 68788-9773
See New Warnings and Directions
Loperamide Hydrochloride Oral Solution
1 mg/5 mL
Anti-Diarrheal
Controls the Symptoms of Diarrhea, including Traveler’s Diarrheal
Each teaspoonful (5 mL) contains: Loperamide Hydrochloride 1 mg
Contains Alcohol 0.5%
Convenient dosage cup enclosed.
4 fl oz (118 mL)
Cherry Mint Flavor
HI-TECH PHARMACAL CO., INC.
Amityville, NY 11701
Relabeled By: Preferred Pharmaceuticals Inc.
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50383-618-04 | ML - Milliliter | 50383-618 | 8b63b39a-50bc-4955-a19f-2bf658aab638 | 1 | 2012-07-24 |
| 50383-618-05 | ML - Milliliter | 50383-618 | cebec501-71fb-4138-b911-b4abaea5d479 | 1 | 2013-10-17 |
| 50383-618-06 | ML - Milliliter | 50383-618 | 4aff43b9-f08c-42f0-891d-7d579728476b | 1 | 2013-08-02 |
| 50383-618-10 | ML - Milliliter | 50383-618 | 87fa7eba-05a0-4c90-b62a-deeca64cc69a | 1 | 2013-10-17 |
| 50383-618-11 | ML - Milliliter | 50383-618 | fdcbc23c-0d0d-4c51-9133-220296523bcb | 1 | 2013-08-02 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| LOPERAMIDE HYDROCHLORIDE | ACTIVE INGREDIENT | 77TI35393C | 2 | |
| LOPERAMIDE | ACTIVE MOIETY | 6X9OC3H4II | 2 | |
| ALCOHOL | INACTIVE INGREDIENT | 3K9958V90M | 2 | |
| ANHYDROUS CITRIC ACID | INACTIVE INGREDIENT | XF417D3PSL | 2 | |
| BENZOIC ACID | INACTIVE INGREDIENT | 8SKN0B0MIM | 2 | |
| CHERRY | INACTIVE INGREDIENT | BUC5I9595W | 2 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 2 | |
| MINT | INACTIVE INGREDIENT | FV98Z8GITP | 2 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 2 | |
| SODIUM BENZOATE | INACTIVE INGREDIENT | OJ245FE5EU | 2 | |
| SORBITOL | INACTIVE INGREDIENT | 506T60A25R | 2 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 68788-9773 | 68788-9773-1 |
| 50383-618 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| LOPERAMIDE HYDROCHLORIDE | 77TI35393C | ACTIB |
| ALCOHOL | 3K9958V90M | IACT |
| ANHYDROUS CITRIC ACID | XF417D3PSL | IACT |
| BENZOIC ACID | 8SKN0B0MIM | IACT |
| CHERRY | BUC5I9595W | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| MINT | FV98Z8GITP | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| SODIUM BENZOATE | OJ245FE5EU | IACT |
| SORBITOL | 506T60A25R | IACT |
| SUCROSE | C151H8M554 | IACT |
| WATER | 059QF0KO0R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION/ DROPS / OPHTHALMIC | 0.75 %w/v | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION / PERINEURAL | 0.02 %w/v | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SOLUTION / ORAL | 3900 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | SOLUTION/ DROPS / OPHTHALMIC | 0.25 %w/v | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / INTRASYNOVIAL | 45 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / TOPICAL | 3633 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION / SUBCUTANEOUS | 149 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRADERMAL | 1.6 %w/v | ||
| SORBITOL | SORBITOL | 506T60A25R | CREAM / TOPICAL | 36.8 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION/ DROPS / TOPICAL | 0.75 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | 9.4 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE / ORAL | 1072 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CREAM / VAGINAL | 1225 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / ORAL | 6624 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | MOUTHWASH / BUCCAL | 200 mg/1ml | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | FILM, SOLUBLE / BUCCAL | 3 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / RECTAL | 1214 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, DELAYED RELEASE / ORAL | 1.7 mg | ||
| BENZOIC ACID | BENZOIC ACID | 8SKN0B0MIM | AEROSOL, FOAM / VAGINAL | 0.1 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / INTRAVENOUS | 1276 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| BENZOIC ACID | BENZOIC ACID | 8SKN0B0MIM | SYRUP / ORAL | 20 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | GRANULE, FOR SUSPENSION / ORAL | 120 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | CAPSULE / ORAL | 1111 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | ELIXIR / ORAL | 9306 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL / TOPICAL | 9971 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, LIQUID FILLED / ORAL | 185 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, CHEWABLE / ORAL | 12 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY, METERED / NASAL | 240 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / TRANSMUCOSAL | 1255 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | GEL / DENTAL | 0.08 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | EMULSION / TOPICAL | 7 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION, SOLUTION / SUBCUTANEOUS | 1.4 %w/v | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | INJECTION / INTRAVENOUS | 864 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / INTRAMUSCULAR | 7459 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION / INTRAVENOUS | 92 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / TOPICAL | 1800 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, COATED / ORAL | 14.21 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CLOTH / TOPICAL | 0.03 mg/mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION/ DROPS / AURICULAR (OTIC) | ADJ PH | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 225 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | PASTE / DENTAL | 14.6 %w/w | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | TABLET, ORALLY DISINTEGRATING / SUBLINGUAL | ADJ PH | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SPRAY / NASAL | 5 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, DELAYED RELEASE / ORAL | 36 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | TABLET, EXTENDED RELEASE / ORAL | 428 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DROPS / ORAL | 300 mg/1ml | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / VAGINAL | 6.4 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION/ DROPS / OPHTHALMIC | 0.75 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL, METERED / TRANSDERMAL | 3675 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A074352-001 | LOPERAMIDE HYDROCHLORIDE | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | c2088c7a36db… | ||
| 2026-09-14 22:38:34 | 2026-08 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 3a93d1ddd44b… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 5135485e-ed86-455e-bc4f-a259760f6fcd | ad232149-329c-4f3d-b1c9-b34975a428fb | 2023-01-16 | Warnings | ad232149-329c-4f3d-b1c9-b34975a428fb |
Adverse event summaries are temporarily unavailable. Other product information remains available.